Combine contrast-enhanced 3D T2-weighted short inversion time inversion recovery MR neurography with MR angiography at 1.5 T in the assessment of brachial plexopathy
Purpose To explore the benefits of using a single injection of contrast agent at a 1.5 T system to perform both contrast-enhanced MR angiography (MRA) and 3D-T2-STIR MR neurography (MRN) to assess of brachial plexopathy. Methods In this prospective study, 27 patients with suspected brachial plexopathy, received an imaging procedure composed sequentially of non-enhanced 3D-T2-STIR, CE-MRA, and contrast-enhanced 3D-T2-STIR, using a 1.5 T MR scanner. Signal intensities and contrast ratios were compared with and without contrast agent. The non-enhanced and contrast-enhanced 3D-T2-STIR images were mixed for two experienced radiologists to rate image diagnostic quality in a blind manner. 3D images of MRN and MRA were merged to reveal the spatial relation between brachial plexopathy and concomitant vascular disorders. Results By comparing the non-enhanced with contrast-enhanced 3D-T2-STIR images, it revealed that the use of the contrast agent in 3D-T2-STIR MRN could significantly suppress the background signals contributed by small vein (P < 0.001), lymph node (P < 0.001), muscle (P < 0.001) and bone (P < 0.001). This improved the contrast ratios between the brachial plexus and its surrounding tissues (P < 0.001) and boosted the image’s quality score (P < 0.01). Examining both CE-MRA and 3D-T2-STIR images revealed a relatively high incidence of concurrent vascular dysfunction in brachial plexopathy, with 39% of confirmed cases accompanied with subclavian and axillary vessel abnormalities. Conclusion Combining contrast-enhanced 3D-T2-STIR MRN with MRA at a 1.5 T system significantly suppresses background signals, improves brachial-plexus display, and provides a direct assessment for both brachial plexus lesion and surrounding vascular injury..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
Magnetic resonance materials in physics, biology and medicine - 34(2020), 2 vom: 13. Juli, Seite 229-239 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Xu, Zhengdao [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Brachial plexopathy |
Anmerkungen: |
© European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) 2020 |
---|
doi: |
10.1007/s10334-020-00867-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2124729799 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2124729799 | ||
003 | DE-627 | ||
005 | 20230505092501.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230505s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10334-020-00867-z |2 doi | |
035 | |a (DE-627)OLC2124729799 | ||
035 | |a (DE-He213)s10334-020-00867-z-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |a 570 |a 530 |q VZ |
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 33.07$jSpektroskopie |2 bkl | ||
084 | |a 35.25$jSpektrochemische Analyse |2 bkl | ||
084 | |a 44.64$jRadiologie |2 bkl | ||
100 | 1 | |a Xu, Zhengdao |e verfasserin |0 (orcid)0000-0001-5096-3217 |4 aut | |
245 | 1 | 0 | |a Combine contrast-enhanced 3D T2-weighted short inversion time inversion recovery MR neurography with MR angiography at 1.5 T in the assessment of brachial plexopathy |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © European Society for Magnetic Resonance in Medicine and Biology (ESMRMB) 2020 | ||
520 | |a Purpose To explore the benefits of using a single injection of contrast agent at a 1.5 T system to perform both contrast-enhanced MR angiography (MRA) and 3D-T2-STIR MR neurography (MRN) to assess of brachial plexopathy. Methods In this prospective study, 27 patients with suspected brachial plexopathy, received an imaging procedure composed sequentially of non-enhanced 3D-T2-STIR, CE-MRA, and contrast-enhanced 3D-T2-STIR, using a 1.5 T MR scanner. Signal intensities and contrast ratios were compared with and without contrast agent. The non-enhanced and contrast-enhanced 3D-T2-STIR images were mixed for two experienced radiologists to rate image diagnostic quality in a blind manner. 3D images of MRN and MRA were merged to reveal the spatial relation between brachial plexopathy and concomitant vascular disorders. Results By comparing the non-enhanced with contrast-enhanced 3D-T2-STIR images, it revealed that the use of the contrast agent in 3D-T2-STIR MRN could significantly suppress the background signals contributed by small vein (P < 0.001), lymph node (P < 0.001), muscle (P < 0.001) and bone (P < 0.001). This improved the contrast ratios between the brachial plexus and its surrounding tissues (P < 0.001) and boosted the image’s quality score (P < 0.01). Examining both CE-MRA and 3D-T2-STIR images revealed a relatively high incidence of concurrent vascular dysfunction in brachial plexopathy, with 39% of confirmed cases accompanied with subclavian and axillary vessel abnormalities. Conclusion Combining contrast-enhanced 3D-T2-STIR MRN with MRA at a 1.5 T system significantly suppresses background signals, improves brachial-plexus display, and provides a direct assessment for both brachial plexus lesion and surrounding vascular injury. | ||
650 | 4 | |a Brachial plexus | |
650 | 4 | |a Magnetic resonance neurography | |
650 | 4 | |a Magnetic resonance angiography | |
650 | 4 | |a Contrast agent | |
650 | 4 | |a Brachial plexopathy | |
700 | 1 | |a Zhang, Tonghua |0 (orcid)0000-0003-1613-1817 |4 aut | |
700 | 1 | |a Chen, Jianxin |0 (orcid)0000-0001-7240-0650 |4 aut | |
700 | 1 | |a Liu, Zongbao |0 (orcid)0000-0002-3033-6213 |4 aut | |
700 | 1 | |a Wang, Tao |0 (orcid)0000-0002-0021-3669 |4 aut | |
700 | 1 | |a Hu, Yijiang |0 (orcid)0000-0003-0036-7980 |4 aut | |
700 | 1 | |a Zhang, Jiahui |0 (orcid)0000-0003-0096-4953 |4 aut | |
700 | 1 | |a Xue, Feifei |0 (orcid)0000-0003-1105-041X |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Magnetic resonance materials in physics, biology and medicine |d Springer International Publishing, 1993 |g 34(2020), 2 vom: 13. Juli, Seite 229-239 |h Online-Ressource |w (DE-627)308449711 |w (DE-600)1502491-X |w (DE-576)113948557 |x 1352-8661 |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2020 |g number:2 |g day:13 |g month:07 |g pages:229-239 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10334-020-00867-z |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_32 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_70 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_90 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_100 | ||
912 | |a GBV_ILN_101 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_120 | ||
912 | |a GBV_ILN_138 | ||
912 | |a GBV_ILN_150 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_152 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_171 | ||
912 | |a GBV_ILN_187 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_224 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_250 | ||
912 | |a GBV_ILN_267 | ||
912 | |a GBV_ILN_281 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_370 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_636 | ||
912 | |a GBV_ILN_702 | ||
912 | |a GBV_ILN_711 | ||
912 | |a GBV_ILN_2001 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2004 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2006 | ||
912 | |a GBV_ILN_2007 | ||
912 | |a GBV_ILN_2008 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2010 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2015 | ||
912 | |a GBV_ILN_2020 | ||
912 | |a GBV_ILN_2021 | ||
912 | |a GBV_ILN_2025 | ||
912 | |a GBV_ILN_2026 | ||
912 | |a GBV_ILN_2027 | ||
912 | |a GBV_ILN_2031 | ||
912 | |a GBV_ILN_2034 | ||
912 | |a GBV_ILN_2037 | ||
912 | |a GBV_ILN_2038 | ||
912 | |a GBV_ILN_2039 | ||
912 | |a GBV_ILN_2044 | ||
912 | |a GBV_ILN_2048 | ||
912 | |a GBV_ILN_2049 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2057 | ||
912 | |a GBV_ILN_2059 | ||
912 | |a GBV_ILN_2061 | ||
912 | |a GBV_ILN_2064 | ||
912 | |a GBV_ILN_2065 | ||
912 | |a GBV_ILN_2068 | ||
912 | |a GBV_ILN_2088 | ||
912 | |a GBV_ILN_2093 | ||
912 | |a GBV_ILN_2106 | ||
912 | |a GBV_ILN_2107 | ||
912 | |a GBV_ILN_2108 | ||
912 | |a GBV_ILN_2110 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_2112 | ||
912 | |a GBV_ILN_2113 | ||
912 | |a GBV_ILN_2118 | ||
912 | |a GBV_ILN_2129 | ||
912 | |a GBV_ILN_2132 | ||
912 | |a GBV_ILN_2143 | ||
912 | |a GBV_ILN_2144 | ||
912 | |a GBV_ILN_2147 | ||
912 | |a GBV_ILN_2148 | ||
912 | |a GBV_ILN_2152 | ||
912 | |a GBV_ILN_2153 | ||
912 | |a GBV_ILN_2188 | ||
912 | |a GBV_ILN_2190 | ||
912 | |a GBV_ILN_2232 | ||
912 | |a GBV_ILN_2336 | ||
912 | |a GBV_ILN_2446 | ||
912 | |a GBV_ILN_2470 | ||
912 | |a GBV_ILN_2474 | ||
912 | |a GBV_ILN_2507 | ||
912 | |a GBV_ILN_2522 | ||
912 | |a GBV_ILN_2548 | ||
912 | |a GBV_ILN_4035 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4046 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4242 | ||
912 | |a GBV_ILN_4246 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4251 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4326 | ||
912 | |a GBV_ILN_4328 | ||
912 | |a GBV_ILN_4333 | ||
912 | |a GBV_ILN_4334 | ||
912 | |a GBV_ILN_4335 | ||
912 | |a GBV_ILN_4336 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4393 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 33.07$jSpektroskopie |q VZ |0 181569957 |0 (DE-625)181569957 |
936 | b | k | |a 35.25$jSpektrochemische Analyse |q VZ |0 106419218 |0 (DE-625)106419218 |
936 | b | k | |a 44.64$jRadiologie |q VZ |0 106409360 |0 (DE-625)106409360 |
951 | |a AR | ||
952 | |d 34 |j 2020 |e 2 |b 13 |c 07 |h 229-239 |